Article in Circulation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Fanglin Ma *Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine (F.M., Y.L., N.G., Y.Z., R.S., B.C.), University of California, Los Angeles (UCLA), Los Angeles, CA.
Yu Liu *Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine (F.M., Y.L., N.G., Y.Z., R.S., B.C.), University of California, Los Angeles (UCLA), Los Angeles, CA.ORCID 0000-0001-5563-6397
Yang XuCardiovascular Research Institute (Y.X., J.C.K.), Icahn School of Medicine at Mount Sinai, New York, NY.
Wenli LiuDivision of Molecular Medicine, Department of Medicine, Columbia University, New York, NY (W.L.).ORCID 0000-0002-1981-611X
Neha GuptaVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine (F.M., Y.L., N.G., Y.Z., R.S., B.C.), University of California, Los Angeles (UCLA), Los Angeles, CA.ORCID 0000-0001-8181-7378
Yiwei ZhuVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine (F.M., Y.L., N.G., Y.Z., R.S., B.C.), University of California, Los Angeles (UCLA), Los Angeles, CA.ORCID 0000-0001-9789-7229
Lieying XiaoDivision of Hematology-Oncology, Department of Medicine and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA (L.X., X.H.).
Steven SweeDepartment of Physiology (S.S., I.A., E.Z., P.P.), University of California, Los Angeles (UCLA), Los Angeles, CA.ORCID 0009-0003-8038-6512
Irsyad AdamDepartment of Physiology (S.S., I.A., E.Z., P.P.), University of California, Los Angeles (UCLA), Los Angeles, CA.ORCID 0009-0000-2288-401X
Erika ZhengDepartment of Physiology (S.S., I.A., E.Z., P.P.), University of California, Los Angeles (UCLA), Los Angeles, CA.ORCID 0009-0001-5319-3593
Peipei PingDepartment of Physiology (S.S., I.A., E.Z., P.P.), University of California, Los Angeles (UCLA), Los Angeles, CA.ORCID 0000-0003-3583-3881
James G TraylorDepartment of Pathology and Translational Pathobiology (J.G.T., O.R., A.Y., A.W.O.), Louisiana State University Health Shreveport, Shreveport, LA.ORCID 0000-0002-7119-6333
Oren RomDepartment of Pathology and Translational Pathobiology (J.G.T., O.R., A.Y., A.W.O.), Louisiana State University Health Shreveport, Shreveport, LA.ORCID 0000-0002-9272-086X
Jason C KovacicCardiovascular Research Institute (Y.X., J.C.K.), Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-4555-769X
Trevor P FidlerDepartment of Physiology, University of San Francisco, CA (T.P.F.).ORCID 0000-0002-0758-9984
Arif YurdagulDepartment of Pathology and Translational Pathobiology (J.G.T., O.R., A.Y., A.W.O.), Louisiana State University Health Shreveport, Shreveport, LA.ORCID 0000-0002-7613-6313
Rajat SinghVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine (F.M., Y.L., N.G., Y.Z., R.S., B.C.), University of California, Los Angeles (UCLA), Los Angeles, CA.ORCID 0000-0001-9389-8574
A Wayne OrrDepartment of Pathology and Translational Pathobiology (J.G.T., O.R., A.Y., A.W.O.), Louisiana State University Health Shreveport, Shreveport, LA.ORCID 0000-0002-2377-213X
Xin HuangDivision of Hematology-Oncology, Department of Medicine and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA (L.X., X.H.).ORCID 0000-0001-6778-8849
Bishuang CaiVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine (F.M., Y.L., N.G., Y.Z., R.S., B.C.), University of California, Los Angeles (UCLA), Los Angeles, CA.ORCID 0000-0002-2047-9923
Funding
Stress Exacerbates Myocardial Ischemic Injury by Blocking Estrogen's Antidoxidant Protection in the Female HeartP20GM121307 · NIGMS · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Vesna Tesic · 2018 to 2026
$23.6M
Tool Core- BoutrosU54HG012517 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BUI, ALEX, PING, PEIPEI · 2022 to 2025
$10.6M
Nck Adaptor Proteins in Atherogenic Endothelial ActivationR01HL133497 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE · 2016 to 2024
$3.8M
New York Consortium for Interdisciplinary Training in Kidney, Urological and Hematological Research (NYC Train KUHR)TL1DK136048 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI JONATHAN M. BARASCH, Wadie F Bahou · 2022 to 2026
$3.8M
EHD1-mediated Inflammation and Resolution in AtherosclerosisR01HL167107 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Bishuang Cai · 2023 to 2026
$2.8M
Efferocytosis meets endocytosisR35GM147269 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Bishuang Cai · 2022 to 2026
$2.3M
Dysregulations in Polyamine Metabolism During AtherosclerosisR01HL167758 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Arif Yurdagul · 2023 to 2026
$2.2M
Disturbed Crosstalk between Cholesterol Homeostasis and Inflammation Resolution in NASHR01DK134610 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Bishuang Cai · 2023 to 2026
$2.2M
EphA2 regulation of atherosclerotic smooth muscle phenotypeR01HL173972 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Anthony Wayne Orr · 2024 to 2026
$2.1M
Lipidated Amino Acids in Cardiometabolic DiseasesR01DK134011 · NIDDK · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Oren Rom · 2022 to 2026
$2.1M
Dysregulated Oxalate Metabolism in Cardiometabolic DiseasesR01DK136685 · NIDDK · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Oren Rom · 2023 to 2026
$1.7M
Nutrient Sensing of Apoptotic Cells by Macrophages Resolves Inflammation, Drives Atherosclerosis Regression, and Promotes Features of Plaque InstabilityR01HL180481 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Arif Yurdagul · 2025 to 2026
backgroundMacrophages are key players in the pathogenesis of atherosclerosis. They trigger immune responses through their cell-surface receptors. However, how macrophages regulate those receptors in response to proinflammatory stimuli is not completely understood. Endocytic membrane trafficking involving receptor internalization, followed by endosomal transport and recycling of the internalized receptors, plays essential roles in balancing cell-surface receptors to meet cellular needs. Here, we explored the role of the endocytic regulator EHD (c-terminal Eps15 [Epidermal growth factor receptor substrate 15] homology domain) 1 in immune responses in macrophages and determined its contribution to atherosclerosis progression.
methodsEHD1 expression profiles in mouse and human plaques were determined by single-cell RNA sequencing and immunofluorescence staining. Bone marrow transplantation by transplanting bone marrow cells from
resultsEHD1 expression in macrophages is enhanced as atherosclerosis progresses in both mice and humans. Histological analysis of aortic root sections from bone marrow transplantation mice showed that EHD1 deletion reduces lesion size. Single-cell RNA sequencing of aortic CD (cluster of differentiation) 45
conclusionsEHD1 promotes inflammation by enhancing TNFR2-NF-κB signaling and stabilizing sortilin, leading to accelerated atherosclerosis. Our study reveals novel roles for EHD1-mediated membrane trafficking in macrophage function and paves the way to innovative therapeutic strategies that aim to address dysregulated membrane trafficking in atherosclerosis.
Indexed as
Adaptor Proteins, Vesicular TransportAtherosclerosisInflammationMacrophagesVesicular Transport ProteinsAnimalsCells, CulturedFemaleHumansMaleMiceMice, Inbred C57BLMice, KnockoutSignal TransductionSortilinAdaptor Proteins, Vesicular TransportEHD1 protein, humanEhd1 protein, mouseSortilinVesicular Transport Proteinsatherosclerosisendocytosisinflammationmacrophagessortilin
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Macrophage EHD1 Promotes Inflammation and Stabilizes Sortilin to Accelerate Atherosclerosis. · full record | Socratic